[PDF] Top 20 Biomarker development in MET-targeted therapy

... the MET receptor kinase have been reported in NSCLC, gastric cancers and HCC ...Variable MET gene amplification rates were detected depending on the detection method ...cancer, MET gene amplification ... See full document

... matched targeted therapies because of the trade-off mentioned ...(7%), MET (7%), RB1 (4%), U2AF1 (3%) CDKN2A (4%) and RIT1 (2%), and very rare mutations as ...contrary, targeted sequencing can ... See full document

... to engineer HSPCs has been tested in a HIV+ patient with highly refractory acute lymphoblastic leukemia (ALL) [120]. In this case, CCR-5 of a fully HLA- matched allogeneic normal donor HSPCs were ablated with CRISPR ... See full document

... to targeted therapy and ascertaining when resistance develops in patients with thyroid cancer has traditionally been difficult, and ctDNA could potentially assist in this ...targeted therapy. ... See full document

... human data together with analysis of the xenograft data- base eliminated the “non-human” factors from the xeno- graft model data sets. Although 887 and 301 genes were differentially expressed in the human and xenograft ... See full document

... design included three cohorts: IGF1R-positive soft tissue sar- comas (group A), IGF1R-positive bone sarcomas (group B), and IGF1R-negative bone and soft tissue sarcomas (group C). An optimal Simon two-stage design was ... See full document

... cartilage targeted therapy that is used in patients with osteoarthritis, on the development and progression of chronic inflammatory arthritis was evaluated in a tumor necrosis factor (TNF) transgenic ... See full document

... ALDH1, an intracellular enzyme that helps detoxify and metabolize many endogenous and exogenous aldehydes, is commonly considered to be a CSC marker in various cancers [17–21]. Among the ALDH1 family subtypes, ALDH1A1 ... See full document

... despite Met not being a key driver in this disease by exploiting its overrepresentation on tumor over normal ...of Met does not alone predict for response to anti-Met TKIs, immunoPET can assess in ... See full document

... Delineation of signal transduction mechanisms involved in the pathogenesis of lymphoma has revealed new therapeutic targets for clinical investigation (Table 1) [6-14]. For example, the ubiquitin-proteasome signaling ... See full document

... Melanoma continues to be a cancer that is exquisitely resistant to treatment. Chemotherapy and immunotherapy have thus far failed to make an impact on survival in the metastatic setting while immunotherapy leads to a ... See full document

... AML therapy and discovered that the mRNA decapping enzyme scavenger (DCPS) gene, which is involved in pre-mRNA metabolic path- ways, is essential for AML cell survival ... See full document

... clinical development of antibody-based HGF or c-Met ...populations, development of biomarkers for HGF/c-Met sig- naling, and identification of effective combination therapies with other RTK ... See full document

... using MET targeted inhibition as a single agent or in combination with other targeted agents, especially EGFR-TKI, remains to be ...testing MET agents are being conducted in combination with ... See full document

... to be a nonessential component in normal cells, as MSLN knockout mice did not present with abnormal development or reproduction [4]. In contrast, preclinical and clinical studies showed that aberrant MSLN expres- ... See full document

... the development of acquired resistance as the major obstacle to long-term disease remission in the ...clinic. MET (or c-MET ) gene amplification has long been known as an important resistance ... See full document

... as Met, is widely present in cells of epithelial origin. HGF/Met signaling is required for normal development and adult homeostasis but is also frequently implicated in cancer, contributing to tumor ... See full document

... performance status was 0 (32%) or 1 (68%), median age was 45 years, the overwhelming majority (92%) had squamous carcinoma, 95% had M1 disease while 5% had recurrent disease, and 35% had received 1% and 65% had received ... See full document

... We report a comprehensive genomic profile and proteomic analysis of two patients with recurrent, metastatic osteosarcoma. Although potential targetable genomic alterations were identified in both tumors, these patients ... See full document

... pure targeted maintenance ...target therapy plays a real role in delaying disease progression during the maintenance ...maintenance therapy for newly diagnosed ovarian ... See full document